| | Adjunctive psychosocial therapies for the treatment of schizophreniaReceived 22 June 2007; received in revised form 4 December 2007; accepted 6 December 2007. published online 16 January 2008. Abstract Antipsychotic pharmacotherapy is the standard of care for the treatment of schizophrenia. Although pharmacotherapy effectively improves some symptoms, others can remain. Pharmacotherapy alone also tends to produce only limited improvement in social functioning and quality of life. Supportive psychosocial therapies have been used as adjuncts to pharmacotherapy to help alleviate residual symptoms and to improve social functioning and quality of life. Additionally, therapies with psychoeducational components can focus on improving medication adherence and reducing relapse and rehospitalization. This review describes the major psychosocial therapeutic strategies that have been used effectively in patients with schizophrenia (cognitive-behavioral therapy, family intervention, social skills, and cognitive remediation), with emphasis on their utility in improving medication adherence. Therapies that integrate various psychosocial therapeutic approaches are also discussed. It is concluded that psychosocial therapy is an effective adjunct to pharmacotherapy for schizophrenia. However, these therapies vary significantly in the functional domains that they address. It is therefore important to identify the form of psychosocial intervention most likely to benefit the individual patient, and to recognize that the effectiveness of any psychosocial intervention could be influenced by such factors as the presence and severity of psychotic or affective symptoms or cognitive impairment. 1. Introduction  Antipsychotic pharmacotherapy is the standard of care for schizophrenia because it effectively controls acute psychotic symptoms. In this regard, atypical antipsychotics represented a significant improvement over first-generation antipsychotics. Atypical antipsychotics, in particular clozapine, are at least as efficacious as typical antipsychotics and have a lower propensity for inducing some types of adverse events, such as extrapyramidal symptoms (Chakos et al., 2001, Luft and Taylor, 2006). However, even with pharmacotherapy, residual symptoms of schizophrenia are common. In one review, it was noted that 10% to 60% of patients experience psychotic symptoms that are resistant to medication (Lindenmayer, 2000). Additionally, medication adherence with antipsychotics is relatively poor (Lieberman et al., 2005, Nasrallah and Lasser, 2006). For example, the Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) reported nonadherence rates of > 60% for every treatment examined (Lieberman et al., 2005). This fact may account at least in part for the high rates of relapse and rehospitalization in patients with schizophrenia, rates that are as high as 30% after 1 year and 80% after 5 years (Dossenbach et al., 2005, Gumley et al., 2006, Robinson et al., 1999). Additionally, symptoms frequently improve during antipsychotic therapy, but functional outcomes do not. A recent publication of data from the CATIE trial noted that only small improvements in psychosocial functioning were observed in patients taking atypical antipsychotics (Swartz et al., 2007). Hence treatment strategies that supplement pharmaceutical therapy are clearly desirable. Psychosocial treatment can directly address a wide range of issues, including adherence, symptom reduction, relapse and hospitalization, patient functionality, and family adjustment. Adherence is particularly important because of its relationship to relapse. Good adherence (ie, levels of ≥80%) has been shown to decrease the risk of hospitalization by as much as 40% (Ward et al., 2006). In reporting the effects of psychosocial treatment as an adjunct to pharmacotherapy, comparisons are often made with pharmacotherapy alone or in combination with “standard care,” which includes such modalities as medication monitoring and supportive counseling. There is evidence to suggest that supportive psychosocial treatment is more cost-effective than standard care (Gutierrez-Recacha et al., 2006, Stant et al., 2003). One study reported that combining psychosocial treatment with pharmacotherapy decreased the average cost of treatment per disability-adjusted life year by more than 40% (Gutierrez-Recacha et al., 2006). An exhaustive review of psychosocial modalities is beyond the scope of this article. Instead, we focus on 4 main categories of psychosocial therapy that have been used effectively in patients with schizophrenia, with emphasis on improvement of medication adherence. Other modalities, such as supported (or “sheltered”) employment, are not addressed in this review. The therapeutic approaches included were identified by a literature search (Medline Ovid 1966 to present) on the terms “schizophrenia AND (psychosocial intervention OR psychosocial therapy OR nonpharmacologic therapy OR psychosocial occupational therapy)”. 2. Overview of psychosocial therapies Psychosocial therapies may be divided into 4 broad categories: cognitive-behavioral therapy (CBT), family intervention therapy (FIT), social skills therapy (SST), and cognitive remediation therapy (CRT) (Pfammatter et al., 2006, Roder et al., 2002). A brief list of specific treatment programs in each category can be found in Table 1. The duration of treatment across and within categories varies from as brief as 6 weeks to as long as 2 years (Bustillo et al., 2001, Pfammatter et al., 2006, Pilling et al., 2002, Zimmermann et al., 2005). | | |  | Program name | Brief description | |
|---|
| Abilities Assessment and Objective Setting (AAOS) (Pioli et al., 2006) | SST and CBT focusing on skill and task objectives and psychoeducation aimed at relapse identification and medication adherence | | | Cognitive Adaptation Training (CAT) (Velligan et al., 2006) | SST and CRT using environmental supports to address apathy and disinhibition in the context of impaired executive function | | | Compliance Therapy (CT) (Kemp et al., 1996) | CBT with focus on improving medication adherence | | | Computer-Assisted Cognitive Strategy Training (CAST) (Vauth et al., 2005) | CRT designed to target cognitive dysfunction | | | Diversified Placement Approach (DPA) (Koop et al., 2004) | SST providing intensive vocational services in stepwise fashion | | | Functional Adaptation Skills Training (FAST) (Patterson et al., 2003, Patterson et al., 2006) | Combines CBT and SST to improve functioning in older patients | | | Functional Cognitive-Behavioral Therapy (FCBT) (Cather, 2005) | CBT with focus on improved social functioning | | | Hallucination-focused Integrated Treatment (HIT) (Wiersma et al., 2004) | CBT and FIT integrated with rehabilitative efforts and mobile crisis intervention to improve coping and antipsychotic medication adherence | | | Indianapolis Vocational Intervention Program (IVIP) (Lysaker et al., 2005) | CBT with focus on negative beliefs impacting vocational function | | | Integrated Psychological Therapy (IPT) (Roder et al., 2006) | Combines group-based CBT with neurocognitive and social cognitive remediation with psychosocial rehabilitation | | | Programa de Entrenamiento para el Desarrollo de Aptitudes para Latinos (PEDAL) (Patterson et al., 2005) | Combines CBT and SST to improve functioning in older Latino patients | | | Psychosocial Occupational Therapy (Allen, 1988) | SST using expressive, artistic, and recreational activities mediated with supportive therapy | | | Training of Self-management Skills for Negative Symptoms (TSSN) (Vauth et al., 2005) | SST designed to target negative symptoms | | | UCLA Social and Independent Living Skills Program (Liberman et al., 1998) | SST in diverse areas of social and daily living | | | | |
Each category has strengths and weaknesses relating to its particular therapeutic focus. A number of integrated strategies combine aspects of CBT, FIT, SST, or CRT in an attempt to enhance the strengths and minimize the weaknesses of each approach (Cather, 2005, Lysaker et al., 2005, Patterson et al., 2005, Patterson et al., 2006, Pioli et al., 2006, Roder et al., 2006, Velligan et al., 2006, Wiersma et al., 2004). Examples of integrated therapies include Functional Adaption Skills Training (FAST), the Program for Training and Development of Skills in Latinos (Programa de Entrenamiento para el Desarrollo de Aptitudes para Latinos, PEDAL), Cognitive Adaptation Training (CAT), and Integrated Psychological Therapy (IPT) (Patterson et al., 2003, Patterson et al., 2005, Patterson et al., 2006, Roder et al., 2006, Velligan et al., 2006). Apart from the obvious need to select the form of psychosocial treatment that best addresses the needs of the individual patient, the usefulness of any psychosocial therapy program may be influenced by such factors as the presence and severity of cognitive or affective disturbances, pharmacotherapeutic control of psychotic symptoms, and the extent of family support and participation in the patient's treatment. 3. Cognitive-behavioral therapy 3.1. Therapeutic focus CBT attempts to achieve reduction of symptoms, reduction of relapse, and enhanced functional capacity by providing rational perspectives on the patient's experience of disease symptoms and responses to them (Dickerson and Lehman, 2006). Within the context of a dialogue, the patient describes his or her experiences with schizophrenia and, with the clinician's help, learns to better understand and cope with those experiences. Simultaneously, the clinician identifies issues that are especially problematic for the patient. CBT exists in several forms, but all of them focus on developing a strong therapeutic alliance and on psycho-education, i.e., informing patients about schizophrenia and psychosis and emphasizing the critical role of medication in controlling symptoms and preventing relapse. Patients thus learn to recognize disease symptoms and early signs of relapse, and they acquire stress reduction techniques, coping strategies, and cognitive restructuring tools to help them deal appropriately with their symptoms (Bellack, 2004). Given the focus of developing a strong patient–physician alliance, traditional CBT does not typically include family members. 3.2. Positive outcomes The most consistent effect of CBT has been the improvement of positive and negative symptoms (Bechdolf et al., 2005a, Bechdolf et al., 2005b, Drury et al., 1996, Gumley et al., 2006, Kemp et al., 1996, Kemp et al., 1998, Kuipers et al., 1997, Sensky et al., 2000, Startup et al., 2005, Tarrier et al., 1999, Tarrier et al., 2004, Temple and Ho, 2005). Recent meta-analyses of CBT support the findings of individual studies (Pfammatter et al., 2006, Zimmermann et al., 2005). In a meta-analysis focusing exclusively on positive symptoms, symptom reduction was 35% greater in CBT patients than in controls, and the success rate for reducing positive symptoms increased from 41% in controls to 59% with CBT (Zimmermann et al., 2005). In this meta-analysis, the overall fixed effect model effect size (FEM ES; in this case, Hedges' g) of CBT on positive symptoms was 0.35, with greater effect during acute psychotic episodes (ES, 0.57) than in the chronic state (ES, 0.27). A meta-analysis of meta-analyses of CBT effects concluded that CBT led to substantial declines in general psychopathology (Hedges' g ES, 0.45) and persistent reductions in positive symptoms (ES, 0.47) (Pfammatter et al., 2006). CBT may also improve medication adherence. Compliance Therapy (CT), a form of CBT developed specifically to improve medication adherence, has been shown to enhance adherence for as long as 18 months after the end of the program (Kemp et al., 1996, Kemp et al., 1998). In another report, CT and behavior-modification regimes were considered effective although the need for more research was acknowledged (Dodds et al., 2000). However, other research has questioned the utility of CT in patients with schizophrenia, finding no notable benefit in terms of improved compliance or positive changes in symptoms, attitude, insight, functionality, or quality of life (O'Donnell et al., 2003), and no clear evidence of advantage over nonspecific patient counseling (McIntosh et al., 2006). The positive effects of CBT can be seen in the early stages of schizophrenia. Applying CBT during the prodromal phase has been reported to reduce global psychopathology, symptoms, and social dysfunction (Bechdolf et al., 2005b). An additional positive outcome associated with CBT is improved mental state (Gumley et al., 2006). The effects of CBT have generally been found to be long-lasting, with effects lasting from 6 months to 2 years after the cessation of treatment (Bechdolf et al., 2005a, Drury et al., 1996, Sensky et al., 2000, Startup et al., 2005, Tarrier et al., 1999, Temple and Ho, 2005). 3.3. Limitations CBT effects on global and social functioning are equivocal (Bechdolf et al., 2005b, Kuipers et al., 1997, Startup et al., 2005, Temple and Ho, 2005), perhaps because of its focus on reducing symptoms and relapse. This limitation is important because poor social and occupational function has been associated with lower perceived quality of life in individuals with schizophrenia (Bengtsson-Tops and Hansson, 1999). The FAST and PEDAL programs were initiated to improve functionality in patients with psychotic disorders (Patterson et al., 2003, Patterson et al., 2005, Patterson et al., 2006). Timing is also relevant. CBT techniques may be more effective during acute psychotic episodes (Zimmermann et al., 2005). Finally, aside from the fact that the reported effectiveness of CBT on medication adherence has been mixed, CBT has not consistently reduced rates of relapse and rehospitalization (Gumley et al., 2006, Startup et al., 2004, Tarrier et al., 2004). Additionally, CBT techniques can be difficult to implement (Siddle and Kingdon, 2000). However, the fact that supportive CBT is the standard of care in the United Kingdom shows that this limitation is not insurmountable and that there is still a widely held perception that CBT is useful in this population. 4. Family intervention therapy 4.1. Therapeutic focus The families of individuals with schizophrenia are affected both financially and emotionally. Furthermore, patients who experience criticism and hostility from their families have been reported to experience relapse more frequently (Vaughan et al., 1992). The Patient Outcomes Research Team (PORT) project has recommended that family intervention be provided to both family and nonfamily caregivers of schizophrenics (Lehman and Steinwachs, 2003). The fundamental components of FIT are psychoeducational. Domains addressed include the illness, family support, crisis intervention, and problem solving (Lehman and Steinwachs, 2003). Family members, and where applicable, the patient as well, learn to better understand both schizophrenia and the critical role that antipsychotic medication adherence plays in reducing the risk of relapse (Pitschel-Walz et al., 2001). In addition, families learn skills that enable them to effectively deal with nonadherence and relapse, as well as techniques they can use to support the patient and to cope with the stress of having a family member with schizophrenia. 4.2. Positive outcomes The most consistently reported positive outcomes of FIT are reductions in relapse and in the number and duration of rehospitalizations (Buchkremer et al., 1997, Falloon et al., 1982, Falloon et al., 1985, Hogarty et al., 1986, Leff et al., 1990, Lenior et al., 2001, Linszen et al., 1996, McFarlane et al., 1995a, McFarlane et al., 1995b, Randolph et al., 1994, Ro-Trock et al., 1977, Tomaras et al., 2000, Xiong et al., 1994). These findings have been confirmed by meta-analyses (Pfammatter et al., 2006, Pilling et al., 2002, Pitschel-Walz et al., 2001). A meta-analysis that included 12 studies of FIT showed that this modality was more effective than standard care at reducing relapse rates at 1- to 2-year follow-up (overall ES, 0.20); however, no clear advantage is seen for FIT over other forms of patient-oriented therapy (Pitschel-Walz et al., 2001). The review of meta-analyses concluded that schizophrenic patients with family participating in therapy had significantly fewer relapses (Hedges' g ES, 0.42 at 6- to 12-month follow-up) and rehospitalizations (ES, 0.51 at 18- to 24-month follow-up) (Pfammatter et al., 2006). Meta-analyses have also indicated that FIT may improve treatment adherence (Pharoah et al., 2006, Pilling et al., 2002). In a comparison with all other treatments, FIT had a greater positive effect on adherence (Hedges' g ES, 0.63) (Pilling et al., 2002). Improved social functioning is commonly reported following FIT, although these findings are less robust than the effects on relapse and hospitalization (Barrowclough and Tarrier, 1990, Chien et al., 2005, Falloon et al., 1987, Li and Arthur, 2005, Magliano et al., 2006a, Magliano et al., 2006b, Veltro et al., 2006). FIT also reduces disease burden on the family and patient (Magliano et al., 2005, Magliano et al., 2006a, Magliano et al., 2006b, Veltro et al., 2006). Reduced disease burden is likely the result of both increased knowledge about schizophrenia and increased coping ability (Li and Arthur, 2005, Magliano et al., 2005). FIT has also been reported to reduce positive symptoms (Falloon et al., 1982, Falloon et al., 1985, Li and Arthur, 2005, Magliano et al., 2005, Montero et al., 2001). The duration of beneficial effects with FIT is variable. Reliable improvements in functional outcome and decreases in disease burden have been reported at 6- to 9-month follow-ups (Magliano et al., 2006a, Magliano et al., 2006b). Positive effects on relapse and rehospitalization have been reported to last for as long as 18 months (Xiong et al., 1994). However, such effects begin to dissipate after 2 years and are generally nonobservable after 5 years (Hogarty et al., 1991, Montero et al., 2006). Therapies that include both patients and family may slightly extend the time to rehospitalization and differentially influence long-term outcome (Montero et al., 2006). 4.3. Limitations FIT may have limited effectiveness early in the course of disease. A study in which the duration of illness was <1 year and 52% of patients were experiencing a first psychotic episode showed no significant effects of FIT (Lenior et al., 2001). In contrast, in studies that have demonstrated the effectiveness of FIT, the average duration of illness ranged from 3 to 10 years (Falloon et al., 1982, Falloon et al., 1985, Li and Arthur, 2005, Magliano et al., 2005, Montero et al., 2001). A major limiting factor for FIT can be a lack of available family members or an unwillingness of family members to participate. This problem may be particularly salient for older patients. Providing FIT to nonfamily caregivers, as suggested by the PORT project (Lehman and Steinwachs, 2003), can partially mitigate this problem. 5. Social skills training 5.1. Therapeutic focus With its focus on improving skills needed for everyday living, SST most directly addresses social functioning and quality of life. SST learning modules cover such areas of dysfunction as self-care, medication and symptom management, basic conversation, vocational skills, and recreation (Liberman et al., 1998). In more complex versions, impairments in information processing are addressed by providing skills for receiving, processing, and sending information. Each skill set is addressed separately in order to facilitate learning. Role play and application in the natural environment are used to increase the probability that acquired skills will generalize after treatment has ended. SST strategies are diverse in addressing such varied domains as occupational and vocational skills training, social milieu training, conversational skills training, assertiveness training, and training in the importance of medication use and disease management (Evans et al., 2004, Glynn et al., 2002, Granholm et al., 2005, Liberman et al., 1998, Marder et al., 1996, Moriana et al., 2006, Shaner et al., 2003, Tsang, 2001, Tsang and Pearson, 2001, Yildiz et al., 2002). 5.2. Positive outcomes Programs that focus on vocational issues, such obtaining employment or enhancing interview skills, have been shown to improve employment outcomes (Evans et al., 2004, Tsang, 2001, Tsang and Pearson, 2001). The meta-analysis of Pfammatter et al. reported Hedges' g ES 0.77 for SST on skill acquisition at the completion of treatment and 0.52 at follow-up (Pfammatter et al., 2006). Programs such as the UCLA Social and Independent Living Skills Program (Liberman et al., 1998, Moriana et al., 2006) are aimed at a wide range of skills. Some reports indicate benefits in functionality (Chien et al., 2003, Liberman et al., 1998, Marder et al., 1996), reduction in comorbid substance abuse (Shaner et al., 2003), and improvement in symptoms (Chien et al., 2003, Dobson et al., 1995, Moriana et al., 2006, Roder et al., 2002, Yildiz et al., 2002); benefits may persist for 1 to 2 years (Liberman et al., 1998, Marder et al., 1996, Roder et al., 2002). 5.3. Limitations The primary limitation of SST is its focus on one or more specific skill sets. Because of this, the probability of generalization to domains outside the skill set(s) is limited. Of particular importance, the effectiveness of SST on medication adherence is uncertain. Some reports indicate measurable benefit (Shaner et al., 2003, Yildiz et al., 2002), but a more recent study found no advantage with SST over standard treatment (Morken et al., 2007). Correspondingly, the effectiveness of SST in reducing relapse risk is also questionable. In at least one study, SST delayed but did not prevent symptom exacerbation (Marder et al., 1996). 6. Cognitive remediation therapy 6.1. Therapeutic focus Cognitive deficits (impaired memory, attention, and executive function) are common among patients with schizophrenia and can significantly impair psychosocial outcome and response to psychosocial treatment (Evans et al., 2003, Green, 1996, Green et al., 2000). Furthermore, the degree of cognitive dysfunction shows direct correlation with the presence and severity of negative symptoms (Greenwood et al., 2005). Unfortunately, cognitive dysfunction is not reliably improved by antipsychotic medications (Daban et al., 2005, Wagner et al., 2005, White et al., 2006). It is hypothesized that addressing cognitive dysfunction through modalities such as CRT will improve patients' insight into schizophrenia and their adherence with pharmacotherapy. Although the ideal is restoration of cognitive function, CRT also employs strategies aimed at compensation for cognitive impairment (Koren et al., 2006, Kurtz et al., 2007, Vauth et al., 2005, Wexler and Bell, 2005). Tactics used in CRT include repetitive supervised exercises, positive reinforcement, and “errorless learning” (in which a task is broken into ordered components, with training proceeding from the simplest components to the more complex). 6.3. Limitations Because CRT is focused on cognition, its effects on overall functioning and psychopathology are less clear. In different reports, CRT reduced symptoms (Cochet et al., 2006) or offered no advantage over usual treatment (Nieznanski et al., 2002). The meta-analysis of Pfammatter et al. found that CRT yielded only modest improvements in general psychopathology and negative symptoms (Hedges' g ES 0.20 and 0.24, respectively) (Pfammatter et al., 2006). Furthermore, even if CRT enhances performance on specific cognitive tasks, it has not yet been conclusively demonstrated that improved neuropsychological test performance translates into improved overall functioning (Bellack, 2004). CRT does not directly target medication adherence, and it is uncertain how long its effects may persist. Based on available evidence, CRT might be most useful as part of a comprehensive program of integrated psychosocial interventions that address overall psychological and social function. 7. Integrated psychosocial therapies The broad approaches discussed above (CBT, SST, FIT, and CRT) improve some, but not all, domains of function. These domains are summarized in Table 2. However, evidence suggests that integrating different approaches into such therapies as FAST, PEDAL, CAT, or IPT (see Table 1) promises to yield more favorable global outcomes. One of the most extensively used programs of this type is IPT, a group-based CBT program that combines neurocognitive and social cognitive remediation therapies (Roder et al., 2006). In a recent meta-analysis of 30 independently conducted studies, IPT significantly improved neurocognition (Cohen's d ES, 0.54), positive symptoms (ES, 0.46), negative symptoms (ES, 0.41), and psychosocial function (ES, 0.41). The superiority of IPT over standard care was maintained for as long as 8 months (Roder et al., 2006). | | | | Intervention | Domains most consistently improved | Domains less consistently improved | |
|---|
| Cognitive-behavioral therapy (CBT) | Psychopathology, residual symptoms | Adherence, social function | | | Family intervention therapy (FIT) | Adherence, relapse, hospitalization, disease burden | Residual symptoms, social function | | | Social skills therapy (SST) | Social function, activities of daily life | Adherence, residual symptoms | | | Cognitive remediation therapy (CRT) | Cognitive function | Residual symptoms, social function | | | Integrated therapies | Social function, residual symptoms | Adherence, relapse | | | | |
In another integrative approach, Patterson and colleagues combined CBT and SST for use in older populations of English-speaking (FAST) and Spanish-speaking (PEDAL) patients with schizophrenia (Patterson et al., 2003, Patterson et al., 2005, Patterson et al., 2006). The FAST program improved social function and negative symptoms, with effects lasting up to 6 months (Patterson et al., 2005). The PEDAL program has been demonstrated to improve social function at a 6-month follow-up, and medication management at an 18-month follow-up. Other integrated programs include CAT, Hallucination-focused Integrative Therapy (HIT), and Psychosocial Assertive Community treatment (Thorup et al., 2005, Velligan et al., 2006, Wiersma et al., 2004). CAT is a complex mix of individualized cognitive-behavioral assessment, skills training, and environmental supports (Velligan et al., 2006). It has been shown to improve functioning, to reduce positive symptoms, and to reduce relapse (Velligan et al., 2000). Psychosocial Assertive Community treatment combines assertive community treatment, SST, and family intervention (Thorup et al., 2005). In 2-year follow-up assessments, this strategy reduced positive and negative symptoms (Thorup et al., 2005).Wiersma et al. reported that the HIT program, a combination of CBT and FIT, significantly improved social functioning and quality of life at 9-month and 18-month follow-up assessments (Wiersma et al., 2004). 8. Conclusions Psychosocial therapy in support of pharmacotherapy in patients with schizophrenia clearly enhances treatment outcomes across a broad range of domains when compared with usual or standard care (Hedges' g ES, 0.23–0.45) (Pfammatter et al., 2006, Zimmermann et al., 2005). In this review, we have emphasized psychosocial interventions that have shown some effectiveness in improving medication adherence. Each therapeutic approach effectively targets selected domains. For CBT, those domains are psychopathology and symptoms; for FIT, adherence, relapse, and rehospitalization; for SST, social skills and employment; and for CRT, neurocognitive function. Integrated psychotherapies offer promise in addressing a wider range of outcomes. Integrated strategies may also be more cost-effective if they can be shown to consistently increase adherence and reduce relapse. For example, a cost savings of 15% was found to be associated with the use of integrated HIT therapy compared with a care-as-usual treatment program consisting of medication monitoring, psychoeducation, and supportive counseling (Stant et al., 2003). However, with the possible exception of IPT, the integrated therapies used to date have not yet demonstrated clear superiority to individual therapeutic approaches in the domains addressed by the individual approaches. In most cases, the effectiveness of psychosocial interventions in support of pharmacotherapy is assessed in comparison with standard care, such as patient education and nonspecific counseling aimed at improved medication compliance. The benefit of education alone has been deemed doubtful (Merinder, 2000, Zygmunt et al., 2002) or inconsistent (Nose and Barbui, 2003), but educational approaches in combination with behavioral approaches may offer more positive results (Dolder et al., 2003). There is general agreement that more definitive research is necessary. Psychosocial therapies can be impeded by common limitations, such as cognitive impairment. Cognitive impairment poses a significant barrier to overall psychosocial function and to the effective implementation of psychosocial therapies (Brekke et al., 2005, Evans et al., 2003, Evans et al., 2004, Sergi et al., 2005). Accordingly, psychosocial therapy may have limited success if neurocognitive remediation is not routinely employed. The efficacy of psychosocial therapy with overly restricted focus may also be limited; for example, therapies that focus primarily on medication management or neurocognitive function may not improve social functioning. These limitations can be overcome when an integrated therapeutic strategy is tailored to the individual. The limited duration of psychosocial therapeutic effects may be more difficult to overcome. Although positive outcomes have been reported as long as 5 years after therapy, most appear to dissipate after about 2 years, which suggests that therapy may need to be continued longer or repeated regularly, if feasible. Improved medication adherence is a particularly important goal for psychosocial therapies because of the link between nonadherence and the risk of relapse. In this regard, FIT should be considered a critical therapeutic strategy. Only FIT has consistently been shown to reduce relapse and rehospitalization, perhaps owing to improvements in adherence. CBT programs that provide psychoeducation concerning adherence and signs of relapse also appear to have some efficacy in this domain. For clinicians treating patients with schizophrenia, the practical issue of employing a psychosocial intervention requires identification of the individual patient's needs and the modality most likely to address them. Additional research into the actual application of the technique or consultation with a practitioner of that technique is certainly advisable. The applicability of psychosocial therapy is limited by the clinician's training, time, and resources. To date, CBT has been administered mainly by individuals who have undergone extensive training, and there is a need for studies documenting the effectiveness of CBT delivered by front-line clinicians who lack this specialized training. Similarly, FIT, SST, and CRT each require extensive training. Training is as important in psychosocial therapy as it is in pharmacotherapy. Although effect sizes of psychosocial therapies may be nearly as large as those observed in medication trials, we view these therapies as adjunctive to pharmacotherapy. Behavioral problems encountered by clinicians are often of long duration, and it may require several sessions of psychosocial therapy to establish substantial symptomatic improvement. Nevertheless, our experience suggests that some form of supportive psychosocial therapy is often important in helping patients achieve optimal clinical and functional outcomes. Demonstration of cost-effectiveness may facilitate implementation of supportive modalities into standard mental health care. Finally, it is important to recognize the need for consensus in defining recovery in schizophrenia, so that the overall effectiveness of psychosocial interventions can be assessed against a uniform standard. Role of funding source Funding for the development of this manuscript and for the editorial assistance was provided by Organon, a part of Schering-Plough, Roseland, NJ. Contributors Drs. Patterson and Leeuwenkamp were involved in all stages of manuscript development and have approved the final version of the manuscript. Conflict of interest Dr. Leeuwenkamp is an employee of NV Organon, a part of Schering-Plough, Oss, The Netherlands. Dr. Patterson declares that he has no conflicts of interest. Acknowledgment Editorial support was provided by Drs. Carl Clay, Brian Kelly, and Craig Slawecki, with funding from Organon, a part of Schering-Plough Roseland, NJ. References Allen, 1988. 1.Allen CK. Occupational therapy: functional assessment of the severity of mental disorders. Hosp. Community Psychiatr. 1988;39(2):140–142. Barrowclough and Tarrier, 1990. 2.Barrowclough C, Tarrier N. Social functioning in schizophrenic patients. I. The effects of expressed emotion and family intervention. Soc. Psychiatry Psychiatr. Epidemiol. 1990;25(3):125–129. MEDLINE |
CrossRef
Bechdolf et al., 2005a. 3.Bechdolf A, Kohn D, Knost B, Pukrop R, Klosterkotter J. A randomized comparison of group cognitive-behavioural therapy and group psychoeducation in acute patients with schizophrenia: outcome at 24 months. Acta Psychiatr. Scand. 2005;112(3):173–179.
CrossRef
Bechdolf et al., 2005b. 4.Bechdolf A, Veith V, Schwarzer D, Schormann M, Stamm E, Janssen B, et al. Cognitive-behavioral therapy in the pre-psychotic phase: an exploratory study. Psychiatry Res. 2005;136(2–3):251–255. Abstract | Full Text |
Full-Text PDF (94 KB)
|
CrossRef
Bellack, 2004. 5.Bellack AS. Skills training for people with severe mental illness. Psychiatr. Rehabil. J. 2004;27(4):375–391.
CrossRef
Bengtsson-Tops and Hansson, 1999. 6.Bengtsson-Tops A, Hansson L. Subjective quality of life in schizophrenic patients living in the community. Relationship to clinical and social characteristics. Eur. Psychiatr. 1999;14(5):256–263. Brekke et al., 2005. 7.Brekke J, Kay DD, Lee KS, Green MF. Biosocial pathways to functional outcome in schizophrenia. Schizophr. Res. 2005;80(2–3):213–225. Abstract | Full Text |
Full-Text PDF (159 KB)
Buchkremer et al., 1997. 8.Buchkremer G, Klingberg S, Holle R, Schulze Monking H, Hornung WP. Psychoeducational psychotherapy for schizophrenic patients and their key relatives or care-givers: results of a 2-year follow-up. Acta Psychiatr. Scand. 1997;96(6):483–491.
CrossRef
Bustillo et al., 2001. 9.Bustillo J, Lauriello J, Horan W, Keith S. The psychosocial treatment of schizophrenia: an update. Am. J. Psychiatry. 2001;158(2):163–175.
CrossRef
Cather, 2005. 10.Cather C. Functional cognitive-behavioural therapy: a brief, individual treatment for functional impairments resulting from psychotic symptoms in schizophrenia. Can. J. Psychiatry. 2005;50(5):258–263. MEDLINE Chakos et al., 2001. 11.Chakos M, Lieberman J, Hoffman E, Bradford D, Sheitman B. Effectiveness of second-generation antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am. J. Psychiatry. 2001;158(4):518–526.
CrossRef
Chien et al., 2003. 12.Chien HC, Ku CH, Lu RB, Chu H, Tao YH, Chou KR. Effects of social skills training on improving social skills of patients with schizophrenia. Arch. Psychiatr. Nurs. 2003;17(5):228–236. Abstract | Full Text |
Full-Text PDF (91 KB)
|
CrossRef
Chien et al., 2005. 13.Chien WT, Chan S, Morrissey J, Thompson D. Effectiveness of a mutual support group for families of patients with schizophrenia. J. Adv. Nurs. 2005;51(6):595–608. MEDLINE |
CrossRef
Cochet et al., 2006. 14.Cochet A, Saoud M, Gabriele S, Broallier V, El Asmar C, Dalery J, et al. Impact of a new cognitive remediation strategy on interpersonal problem solving skills and social autonomy in schizophrenia. Encephale. 2006;32(2 Pt 1):189–195. MEDLINE |
CrossRef
Daban et al., 2005. 15.Daban C, Amado I, Bourdel MC, Loo H, Olie JP, Poirier MF, et al. Cognitive dysfunctions in medicated and unmedicated patients with recent-onset schizophrenia. J. Psychiatr. Res. 2005;39(4):391–398. MEDLINE |
CrossRef
Dickerson and Lehman, 2006. 16.Dickerson FB, Lehman AF. Evidence-based psychotherapy for schizophrenia. J. Nerv. Ment. Dis. 2006;194(1):3–9. MEDLINE |
CrossRef
Dobson et al., 1995. 17.Dobson DJ, McDougall G, Busheikin J, Aldous J. Effects of social skills training and social milieu treatment on symptoms of schizophrenia. Psychiatr. Serv. 1995;46(4):376–380. MEDLINE Dodds et al., 2000. 18.Dodds F, Rebair-Brown A, Parsons S. A systematic review of randomized controlled trials that attempt to identify interventions that improve patient compliance with prescribed antipsychotic medication. Clin. Eff. Nurs. 2000;4:47–53. Dolder et al., 2003. 19.Dolder CR, Lacro JP, Leckband S, Jeste DV. Interventions to improve antipsychotic medication adherence: review of recent literature. J. Clin. Psychopharmacol. 2003;23(4):389–399. MEDLINE |
CrossRef
Dossenbach et al., 2005. 20.Dossenbach M, Arango-Davila C, Silva Ibarra H, Landa E, Aguilar J, Caro O, et al. Response and relapse in patients with schizophrenia treated with olanzapine, risperidone, quetiapine, or haloperidol: 12-month follow-up of the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. J. Clin. Psychiatry. 2005;66(8):1021–1030. MEDLINE |
CrossRef
Drury et al., 1996. 21.Drury V, Birchwood M, Cochrane R, Macmillan F. Cognitive therapy and recovery from acute psychosis: a controlled trial. I. Impact on psychotic symptoms. Br. J. Psychiatry. 1996;169(5):593–601. MEDLINE |
CrossRef
Evans et al., 2003. 22.Evans JD, Heaton RK, Paulsen JS, Palmer BW, Patterson T, Jeste DV. The relationship of neuropsychological abilities to specific domains of functional capacity in older schizophrenia patients. Biol. Psychiatry. 2003;53(5):422–430. Abstract | Full Text |
Full-Text PDF (95 KB)
|
CrossRef
Evans et al., 2004. 23.Evans JD, Bond GR, Meyer PS, Kim HW, Lysaker PH, Gibson PJ, et al. Cognitive and clinical predictors of success in vocational rehabilitation in schizophrenia. Schizophr. Res. 2004;70(2–3):331–342. Abstract | Full Text |
Full-Text PDF (147 KB)
|
CrossRef
Falloon et al., 1982. 24.Falloon IR, Boyd JL, McGill CW, Razani J, Moss HB, Gilderman AM. Family management in the prevention of exacerbations of schizophrenia: a controlled study. N. Engl. J. Med. 1982;306(24):1437–1440. MEDLINE |
CrossRef
Falloon et al., 1985. 25.Falloon IR, Boyd JL, McGill CW, Williamson M, Razani J, Moss HB, et al. Family management in the prevention of morbidity of schizophrenia. Clinical outcome of a two-year longitudinal study. Arch. Gen. Psychiatry. 1985;42(9):887–896. Falloon et al., 1987. 26.Falloon IR, McGill CW, Boyd JL, Pederson J. Family management in the prevention of morbidity of schizophrenia: social outcome of a two-year longitudinal study. Psychol. Med. 1987;17(1):59–66. MEDLINE |
CrossRef
Glynn et al., 2002. 27.Glynn SM, Marder SR, Liberman RP, Blair K, Wirshing WC, Wirshing DA, et al. Supplementing clinic-based skills training with manual-based community support sessions: effects on social adjustment of patients with schizophrenia. Am. J. Psychiatry. 2002;159(5):829–837.
CrossRef
Granholm et al., 2005. 28.Granholm E, McQuaid JR, McClure FS, Auslander LA, Perivoliotis D, Pedrelli P, et al. A randomized, controlled trial of cognitive behavioral social skills training for middle-aged and older outpatients with chronic schizophrenia. Am. J. Psychiatry. 2005;162(3):520–529.
CrossRef
Green, 1996. 29.Green MF. What are the functional consequences of neurocognitive deficits in schizophrenia?. Am. J. Psychiatry. 1996;153(3):321–330. Green et al., 2000. 30.Green MF, Kern RS, Braff DL, Mintz J. Neurocognitive deficits and functional outcome in schizophrenia: are we measuring the “right stuff”?. Schizophr. Bull. 2000;26(1):119–136. MEDLINE Greenwood et al., 2005. 31.Greenwood KE, Landau S, Wykes T. Negative symptoms and specific cognitive impairments as combined targets for improved functional outcome within cognitive remediation therapy. Schizophr. Bull. 2005;31(4):910–921. MEDLINE |
CrossRef
Gumley et al., 2006. 32.Gumley A, Karatzias A, Power K, Reilly J, McNay L, O'Grady M. Early intervention for relapse in schizophrenia: impact of cognitive behavioural therapy on negative beliefs about psychosis and self-esteem. Br. J. Clin. Psychol. 2006;45(Pt 2):247–260. MEDLINE |
CrossRef
Gutierrez-Recacha et al., 2006. 33.Gutierrez-Recacha P, Chisholm D, Haro JM, Salvador-Carulla L, Ayuso-Mateos JL. Cost-effectiveness of different clinical interventions for reducing the burden of schizophrenia in Spain. Acta Psychiatr. Scand., Suppl. 2006;432:29–38. Hogarty et al., 1986. 34.Hogarty GE, Anderson CM, Reiss DJ, Kornblith SJ, Greenwald DP, Javna CD, et al. Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. I. One-year effects of a controlled study on relapse and expressed emotion. Arch. Gen. Psychiatry. 1986;43(7):633–642. Hogarty et al., 1991. 35.Hogarty GE, Anderson CM, Reiss DJ, Kornblith SJ, Greenwald DP, Ulrich RF, et al. Family psychoeducation, social skills training, and maintenance chemotherapy in the aftercare treatment of schizophrenia. II. Two-year effects of a controlled study on relapse and adjustment. Environmental-Personal Indicators in the Course of Schizophrenia (EPICS) Research Group. Arch. Gen. Psychiatry. 1991;48(4):340–347. Kemp et al., 1996. 36.Kemp R, Hayward P, Applewhaite G, Everitt B, David A. Compliance therapy in psychotic patients: randomised controlled trial. BMJ. 1996;312(7027):345–349. Kemp et al., 1998. 37.Kemp R, Kirov G, Everitt B, Hayward P, David A. Randomised controlled trial of compliance therapy. 18-month follow-up. Br. J. Psychiatry. 1998;172:413–419. MEDLINE |
CrossRef
Koop et al., 2004. 38.Koop JI, Rollins AL, Bond GR, Salyers MP, Dincin J, Kinley T, et al. Development of the DPA Fidelity Scale: using fidelity to define an existing vocational model. Psychiatr. Rehabil. J. 2004;28(1):16–24.
CrossRef
Koren et al., 2006. 39.Koren D, Seidman LJ, Goldsmith M, Harvey PD. Real-world cognitive-and metacognitive-dysfunction in schizophrenia: a new approach for measuring (and remediating) more “right stuff”. Schizophr. Bull. 2006;32(2):310–326. MEDLINE |
CrossRef
Kuipers et al., 1997. 40.Kuipers E, Garety P, Fowler D, Dunn G, Bebbington P, Freeman D, et al. London-East Anglia randomised controlled trial of cognitive-behavioural therapy for psychosis. I: effects of the treatment phase. Br. J. Psychiatry. 1997;171:319–327. MEDLINE |
CrossRef
Kurtz et al., 2007. 41.Kurtz MM, Seltzer JC, Shagan DS, Thime WR, Wexler BE. Computer-assisted cognitive remediation in schizophrenia: what is the active ingredient?. Schizophr. Res. 2007;89(1–3):251–260. Abstract | Full Text |
Full-Text PDF (180 KB)
|
CrossRef
Leff et al., 1990. 42.Leff J, Berkowitz R, Shavit N, Strachan A, Glass I, Vaughn C. A trial of family therapy versus a relatives' group for schizophrenia. Two-year follow-up. Br. J. Psychiatry. 1990;157:571–577. MEDLINE |
CrossRef
Lehman and Steinwachs, 2003. 43.Lehman AF, Steinwachs DM. Evidence-based psychosocial treatment practices in schizophrenia: lessons from the patient outcomes research team (PORT) project. J. Amer. Acad. Psychoanal. Dyn. Psychiatry. 2003;31(1):141–154. Lenior et al., 2001. 44.Lenior ME, Dingemans PM, Linszen DH, de Haan L, Schene AH. Social functioning and the course of early-onset schizophrenia: five-year follow-up of a psychosocial intervention. Br. J. Psychiatry. 2001;179:53–58. MEDLINE |
CrossRef
Li and Arthur, 2005. 45.Li Z, Arthur D. Family education for people with schizophrenia in Beijing, China: randomised controlled trial. Br. J. Psychiatry. 2005;187:339–345. MEDLINE |
CrossRef
Liberman et al., 1998. 46.Liberman RP, Wallace CJ, Blackwell G, Kopelowicz A, Vaccaro JV, Mintz J. Skills training versus psychosocial occupational therapy for persons with persistent schizophrenia. Am. J. Psychiatry. 1998;155(8):1087–1091. Lieberman et al., 2005. 47.Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med. 2005;353(12):1209–1223.
CrossRef
Lindenmayer, 2000. 48.Lindenmayer JP. Treatment refractory schizophrenia. Psychiatr. Q. 2000;71(4):373–384. MEDLINE |
CrossRef
Linszen et al., 1996. 49.Linszen D, Dingemans P, Van der Does JW, Nugter A, Scholte P, Lenior R, et al. Treatment, expressed emotion and relapse in recent onset schizophrenic disorders. Psychol. Med. 1996;26(2):333–342. MEDLINE |
CrossRef
Luft and Taylor, 2006. 50.Luft B, Taylor D. A review of atypical antipsychotic drugs versus conventional medication in schizophrenia. Expert Opin. Pharmacother. 2006;7(13):1739–1748.
CrossRef
Lysaker et al., 2005. 51.Lysaker PH, Bond G, Davis LW, Bryson GJ, Bell MD. Enhanced cognitive-behavioral therapy for vocational rehabilitation in schizophrenia: Effects on hope and work. J. Rehabil. Res. Dev. 2005;42(5):673–682. MEDLINE |
CrossRef
Magliano et al., 2005. 52.Magliano L, Fiorillo A, Fadden G, Gair F, Economou M, Kallert T, et al. Effectiveness of a psychoeducational intervention for families of patients with schizophrenia: preliminary results of a study funded by the European Commission. World Psychiatry. 2005;4(1):45–49. Magliano et al., 2006a. 53.Magliano L, Fiorillo A, Malangone C, De Rosa C, Favata G, Sasso A, et al. Family psychoeducational interventions for schizophrenia in routine settings: impact on patients' clinical status and social functioning and on relatives' burden and resources. Epidemiol. Psichiatr. Soc. 2006;15(3):219–227. Magliano et al., 2006b. 54.Magliano L, Fiorillo A, Malangone C, De Rosa C, Maj M. Patient functioning and family burden in a controlled, real-world trial of family psychoeducation for schizophrenia. Psychiatr. Serv. 2006;57(12):1784–1791. MEDLINE |
CrossRef
Marder et al., 1996. 55.Marder SR, Wirshing WC, Mintz J, McKenzie J, Johnston K, Eckman TA, et al. Two-year outcome of social skills training and group psychotherapy for outpatients with schizophrenia. Am. J. Psychiatry. 1996;153(12):1585–1592. McFarlane et al., 1995a. 56.McFarlane WR, Link B, Dushay R, Marchal J, Crilly J. Psychoeducational multiple family groups: four-year relapse outcome in schizophrenia. Fam. Proc. 1995;34(2):127–144. McFarlane et al., 1995b. 57.McFarlane WR, Lukens E, Link B, Dushay R, Deakins SA, Newmark M, et al. Multiple-family groups and psychoeducation in the treatment of schizophrenia. Arch. Gen. Psychiatry. 1995;52(8):679–687. McGurk et al., 2005. 58.McGurk SR, Mueser KT, Pascaris A. Cognitive training and supported employment for persons with severe mental illness: one-year results from a randomized controlled trial. Schizophr. Bull. 2005;31(4):898–909. MEDLINE |
CrossRef
McIntosh et al., 2006. 59.McIntosh AM, Conlon L, Lawrie SM, Stanfield AC. Compliance therapy for schizophrenia. Cochrane Database Syst. Rev. 2006;3:CD003442. Merinder, 2000. 60.Merinder LB. Patient education in schizophrenia: a review. Acta Psychiatr. Scand. 2000;102(2):98–106. Montero et al., 2001. 61.Montero I, Asencio A, Hernandez I, Masanet MJ, Lacruz M, Bellver F, et al. Two strategies for family intervention in schizophrenia: a randomized trial in a Mediterranean environment. Schizophr. Bull. 2001;27(4):661–670. MEDLINE Montero et al., 2006. 62.Montero I, Masanet MJ, Bellver F, Lacruz M. The long-term outcome of 2 family intervention strategies in schizophrenia. Compr. Psychiatry. 2006;47(5):362–367.
CrossRef
Moriana et al., 2006. 63.Moriana JA, Alarcon E, Herruzo J. In-home psychosocial skills training for patients with schizophrenia. Psychiatr. Serv. 2006;57(2):260–262. MEDLINE Morken et al., 2007. 64.Morken G, Grawe RW, Widen JH. Effects of integrated treatment on antipsychotic medication adherence in a randomized trial in recent-onset schizophrenia. J. Clin. Psychiatry. 2007;68(4):566–571.
CrossRef
Nasrallah and Lasser, 2006. 65.Nasrallah HA, Lasser R. Improving patient outcomes in schizophrenia: achieving remission. J. Psychopharmacol. 2006;20(6 Suppl):57–61. MEDLINE |
CrossRef
Nieznanski et al., 2002. 66.Nieznanski M, Czerwinska M, Chojnowska A, Walczak S, Dunski W. Effectiveness of cognitive skills training in schizophrenia. Psychiatr. Pol. 2002;36(5):745–757. MEDLINE Nose and Barbui, 2003. 67.Nose M, Barbui C. Systemic review of clinical interventions for reducing treatment non-adherence in psychosis. Epidemiol. Psichiatr. Soc. 2003;12(4):272–286. O'Donnell et al., 2003. 68.O'Donnell C, Donohoe G, Sharkey L, Owens N, Migone M, Harries R, et al. Compliance therapy: a randomised controlled trial in schizophrenia. BMJ. 2003;327(7419):834. Patterson et al., 2003. 69.Patterson TL, McKibbin C, Taylor M, Goldman S, Davila-Fraga W, Bucardo J, et al. Functional adaptation skills training (FAST): a pilot psychosocial intervention study in middle-aged and older patients with chronic psychotic disorders. Am. J. Geriatr. Psychiatry. 2003;11(1):17–23. MEDLINE |
CrossRef
Patterson et al., 2005. 70.Patterson TL, Bucardo J, McKibbin CL, Mausbach BT, Moore D, Barrio C, et al. Development and pilot testing of a new psychosocial intervention for older Latinos with chronic psychosis. Schizophr. Bull. 2005;31(4):922–930. MEDLINE |
CrossRef
Patterson et al., 2006. 71.Patterson TL, Mausbach BT, McKibbin C, Goldman S, Bucardo J, Jeste DV. Functional Adaptation Skills Training (FAST): a randomized trial of a psychosocial intervention for middle-aged and older patients with chronic psychotic disorders. Schizophr. Res. 2006;86(1–3):291–299. Abstract | Full Text |
Full-Text PDF (232 KB)
|
CrossRef
Pfammatter et al., 2006. 72.Pfammatter M, Junghan UM, Brenner HD. Efficacy of psychological therapy in schizophrenia: conclusions from meta-analyses. Schizophr. Bull. 2006;32(1 Suppl):S64–S80.
CrossRef
Pharoah et al., 2006. 73.Pharoah F, Mari J, Rathbone J, Wong W. Family intervention for schizophrenia. Cochrane Database Syst. Rev. 2006;4:CD000088. Pilling et al., 2002. 74.Pilling S, Bebbington P, Kuipers E, Garety P, Geddes J, Orbach G, et al. Psychological treatments in schizophrenia: I. Meta-analysis of family intervention and cognitive behaviour therapy. Psychol. Med. 2002;32(5):763–782. MEDLINE Pioli et al., 2006. 75.Pioli R, Vittorielli M, Gigantesco A, Rossi G, Basso L, Caprioli C, et al. Outcome assessment of the VADO approach in psychiatric rehabilitation: a partially randomised multicentric trial. Clin. Pract. Epidemol. Ment. Health. 2006;2:5. Pitschel-Walz et al., 2001. 76.Pitschel-Walz G, Leucht S, Bauml J, Kissling W, Engel RR. The effect of family interventions on relapse and rehospitalization in schizophrenia—a meta-analysis. Schizophr. Bull. 2001;27(1):73–92. MEDLINE Randolph et al., 1994. 77.Randolph ET, Eth S, Glynn SM, Paz GG, Leong GB, Shaner AL, et al. Behavioural family management in schizophrenia. Outcome of a clinic-based intervention. Br. J. Psychiatry. 1994;164(4):501–506. MEDLINE |
CrossRef
Ro-Trock et al., 1977. 78.Ro-Trock GK, Wellisch DK, Schoolar JC. A family therapy outcome study in an inpatient setting. Am. J. Orthopsychiatr. 1977;47(3):514–522. Robinson et al., 1999. 79.Robinson D, Woerner MG, Alvir JM, Bilder R, Goldman R, Geisler S, et al. Predictors of relapse following response from a first episode of schizophrenia or schizoaffective disorder. Arch. Gen. Psychiatry. 1999;56(3):241–247.
CrossRef
Roder et al., 2002. 80.Roder V, Brenner HD, Muller D, Lachler M, Zorn P, Reisch T, et al. Development of specific social skills training programmes for schizophrenia patients: results of a multicentre study. Acta Psychiatr. Scand. 2002;105(5):363–371.
CrossRef
Roder et al., 2006. 81.Roder V, Mueller DR, Mueser KT, Brenner HD. Integrated psychological therapy (IPT) for schizophrenia: is it effective?. Schizophr. Bull. 2006;32(Suppl 1):S81–S93.
CrossRef
Sensky et al., 2000. 82.Sensky T, Turkington D, Kingdon D, Scott JL, Scott J, Siddle R, et al. A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication. Arch. Gen. Psychiatry. 2000;57(2):165–172.
CrossRef
Sergi et al., 2005. 83.Sergi MJ, Kern RS, Mintz J, Green MF. Learning potential and the prediction of work skill acquisition in schizophrenia. Schizophr. Bull. 2005;31(1):67–72. MEDLINE |
CrossRef
Shaner et al., 2003. 84.Shaner A, Eckman T, Roberts LJ, Fuller T. Feasibility of a skills training approach to reduce substance dependence among individuals with schizophrenia. Psychiatr. Serv. 2003;54(9):1287–1289. MEDLINE |
CrossRef
Siddle and Kingdon, 2000. 85.Siddle R, Kingdon D. The management of schizophrenia: cognitive behavioural therapy. Br. J. Community Nurs. 2000;5(1):20–25. MEDLINE Stant et al., 2003. 86.Stant AD, TenVergert EM, Groen H, Jenner JA, Nienhuis FJ, van de Willige G, et al. Cost-effectiveness of the HIT programme in patients with schizophrenia and persistent auditory hallucinations. Acta Psychiatr. Scand. 2003;107(5):361–368.
CrossRef
Startup et al., 2004. 87.Startup M, Jackson MC, Bendix S. North Wales randomized controlled trial of cognitive behaviour therapy for acute schizophrenia spectrum disorders: outcomes at 6 and 12 months. Psychol. Med. 2004;34(3):413–422. MEDLINE |
CrossRef
Startup et al., 2005. 88.Startup M, Jackson MC, Evans KE, Bendix S. North Wales randomized controlled trial of cognitive behaviour therapy for acute schizophrenia spectrum disorders: two-year follow-up and economic evaluation. Psychol. Med. 2005;35(9):1307–1316. MEDLINE |
CrossRef
Swartz et al., 2007. 89.Swartz MS, Perkins DO, Stroup TS, Davis SM, Capuano G, Rosenheck RA, et al. Effects of antipsychotic medications on psychosocial functioning in patients with chronic schizophrenia: findings from the NIMH CATIE study. Am. J. Psychiatry. 2007;164(3):428–436.
CrossRef
Tarrier et al., 1999. 90.Tarrier N, Wittkowski A, Kinney C, McCarthy E, Morris J, Humphreys L. Durability of the effects of cognitive-behavioural therapy in the treatment of chronic schizophrenia: 12-month follow-up. Br. J. Psychiatry. 1999;174:500–504. MEDLINE |
CrossRef
Tarrier et al., 2004. 91.Tarrier N, Lewis S, Haddock G, Bentall R, Drake R, Kinderman P, et al. Cognitive-behavioural therapy in first-episode and early schizophrenia. 18-month follow-up of a randomised controlled trial. Br. J. Psychiatry. 2004;184:231–239. MEDLINE |
CrossRef
Temple and Ho, 2005. 92.Temple S, Ho BC. Cognitive therapy for persistent psychosis in schizophrenia: a case-controlled clinical trial. Schizophr. Res. 2005;74(2–3):195–199. Abstract | Full Text |
Full-Text PDF (84 KB)
|
CrossRef
Thorup et al., 2005. 93.Thorup A, Petersen L, Jeppesen P, Ohlenschlaeger J, Christensen T, Krarup G, et al. Integrated treatment ameliorates negative symptoms in first episode psychosis—results from the Danish OPUS trial. Schizophr. Res. 2005;79(1):95–105. Abstract | Full Text |
Full-Text PDF (131 KB)
|
CrossRef
Tomaras et al., 2000. 94.Tomaras V, Mavreas V, Economou M, Ioannovich E, Karydi V, Stefanis C. The effect of family intervention on chronic schizophrenics under individual psychosocial treatment: a 3-year study. Soc. Psychiatry Psychiatr. Epidemiol. 2000;35(11):487–493. MEDLINE |
CrossRef
Tsang, 2001. 95.Tsang HW. Applying social skills training in the context of vocational rehabilitation for people with schizophrenia. J. of Nerv. Ment. Dis. 2001;189(2):90–98. Tsang and Pearson, 2001. 96.Tsang HW, Pearson V. Work-related social skills training for people with schizophrenia in Hong Kong. Schizophr. Bull. 2001;27(1):139–148. MEDLINE Vaughan et al., 1992. 97.Vaughan K, Doyle M, McConaghy N, Blaszczynski A, Fox A, Tarrier N. The relationship between relative's Expressed Emotion and schizophrenic relapse: an Australian replication. Soc. Psychiatry Psychiatr. Epidemiol. 1992;27(1):10–15. MEDLINE |
CrossRef
Vauth et al., 2005. 98.Vauth R, Corrigan PW, Clauss M, Dietl M, Dreher-Rudolph M, Stieglitz RD, et al. Cognitive strategies versus self-management skills as adjunct to vocational rehabilitation. Schizophr. Bull. 2005;31(1):55–66. MEDLINE |
CrossRef
Velligan et al., 2000. 99.Velligan DI, Bow-Thomas CC, Huntzinger C, Ritch J, Ledbetter N, Prihoda TJ, et al. Randomized controlled trial of the use of compensatory strategies to enhance adaptive functioning in outpatients with schizophrenia. Am. J. Psychiatry. 2000;157(8):1317–1323.
CrossRef
Velligan et al., 2006. 100.Velligan DI, Mueller J, Wang M, Dicocco M, Diamond PM, Maples NJ, et al. Use of environmental supports among patients with schizophrenia. Psychiatr. Serv. 2006;57(2):219–224. MEDLINE Veltro et al., 2006. 101.Veltro F, Magliano L, Morosini P, Fasulo E, Pedicini G, Cascavilla I, et al. Randomised controlled trial of a behavioural family intervention: 1 year and 11-years follow-up. Epidemiol. Psichiatr. Soc. 2006;15(1):44–51. Wagner et al., 2005. 102.Wagner M, Quednow BB, Westheide J, Schlaepfer TE, Maier W, Kuhn KU. Cognitive improvement in schizophrenic patients does not require a serotonergic mechanism: randomized controlled trial of olanzapine vs amisulpride. Neuropsychopharmacology. 2005;30(2):381–390.
CrossRef
Ward et al., 2006. 103.Ward A, Ishak K, Proskorovsky I, Caro J. Compliance with refilling prescriptions for atypical antipsychotic agents and its association with the risks for hospitalization, suicide, and death in patients with schizophrenia in Quebec and Saskatchewan: a retrospective database study. Clin. Ther. 2006;28(11):1912–1921. Abstract |
Full-Text PDF (950 KB)
|
CrossRef
Wexler and Bell, 2005. 104.Wexler BE, Bell MD. Cognitive remediation and vocational rehabilitation for schizophrenia. Schizophr. Bull. 2005;31(4):931–941. MEDLINE |
CrossRef
White et al., 2006. 105.White L, Friedman JI, Bowie CR, Evers M, Harvey PD, Parrella M, et al. Long-term outcomes in chronically hospitalized geriatric patients with schizophrenia: retrospective comparison of first generation and second generation antipsychotics. Schizophr. Res. 2006;88(1–3):127–134. Abstract | Full Text |
Full-Text PDF (151 KB)
|
CrossRef
Wiersma et al., 2004. 106.Wiersma D, Jenner JA, Nienhuis FJ, van de Willige G. Hallucination focused integrative treatment improves quality of life in schizophrenia patients. Acta Psychiatr. Scand. 2004;109(3):194–201.
CrossRef
Xiong et al., 1994. 107.Xiong W, Phillips MR, Hu X, Wang R, Dai Q, Kleinman J, et al. Family-based intervention for schizophrenic patients in China. A randomised controlled trial. Br. J. Psychiatry. 1994;165(2):239–247. MEDLINE |
CrossRef
Yildiz et al., 2002. 108.Yildiz M, Yazici A, Unal S, Aker T, Ozgen G, Ekmekci H, et al. Social skills training in psychosocial therapy of schizophrenia: a multicenter study for symptom management and medication management modules. Turk. Psikiyatri. Derg. 2002;13(1):41–47. Zimmermann et al., 2005. 109.Zimmermann G, Favrod J, Trieu VH, Pomini V. The effect of cognitive behavioral treatment on the positive symptoms of schizophrenia spectrum disorders: a meta-analysis. Schizophr. Res. 2005;77(1):1–9. Abstract | Full Text |
Full-Text PDF (155 KB)
|
CrossRef
Zygmunt et al., 2002. 110.Zygmunt A, Olfson M, Boyer CA, Mechanic D. Interventions to improve medication adherence in schizophrenia. Am. J. Psychiatry. 2002;159(10):1653–1664.
CrossRef
a Department of Psychiatry, University of California, San Diego, La Jolla, CA 92093-0680, United States b NV Organon, a part of Schering-Plough, Oss, The Netherlands  Corresponding author. Tel.: +1 858 534 3354; fax: +1 858 534 7723.
PII: S0920-9964(07)01038-9 doi:10.1016/j.schres.2007.12.468 © 2007 Elsevier B.V. All rights reserved. | |
|
FULL TEXT